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Abstract 
Objective: In beta thalassemic patients, tissue damage occurs due to oxidative stress and it 
happens because of the accumulation of iron in the body. This study was conducted to determine 
the effect of zinc and vitamin E supplementation on antioxidant status in beta-thalassemic major 
patients. 
Methods: This double blind randomized clinical trial was carried out on 120 beta thalassemic 
patients older than 18 years. Patients were randomly categorized in four groups. Zinc (50mg/day) 
and vitamin E (400mg/day) supplements were administered for former and latter group, 
respectively. In the third group both supplements were administered in similar doses. The fourth 
(control) group received no supplement. The effect of supplementations on serum zinc and vitamin 
E, superoxide dismutase (SOD), glutathione peroxidase (GPX), total antioxidant capacity (TAC) and 
body mass index (BMI) were measured at the beginning and the end of the study. 
Findings: Serum zinc levels in group 1 and 3 were significantly increased (P<0.007 and P<0.005, 
respectively). Serum vitamin E levels in group 2 and 3 were also increased significantly (P<0.001). 
Mean GPX activity in group1, 2 and 3 decreased significantly (P<0.015, P<0.032 and P<0.029, 
respectively). Mean SOD activity and TAC did not show significant change after supplementation. 
BMI had significant increase in all treated groups (P<0.001).  
Conclusion: Our results suggest that beta thalassemic patients have enhanced oxidative stress and 
administration of selective antioxidants may preclude oxidative damage. 
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Introduction 
Beta-thalassemia major results from acute 
reduction or lack of synthesis of beta globin chains 
and can be produced by gene mutations. 
     This causes much of the production of alpha-
globin chains which are not able to produce 
hemoglobin tetramer[1]. Nearly 200 million people 
in the world are affected by thalassemia 
syndromes[2]. The prevalence of thalassemia gene 
in the world is about 3%. About 15,000 people are 
known as thalassemic in Iran, and about 3,000,000 
people are carrying thalassemia gene[3]. 
     In beta thalassemia major, tissue damage occurs 
due to oxidative stress, and it happens because of 
the accumulation of iron in the body. Spontaneous 
oxidation of unpaired alpha-globin chains leads to 
production of super oxide ions and hydrogen 
peroxide[4-7]. 
     Reduction in the Total Peroxyl Radical Trapping 
Capacity (TRAP), which indicates decreased 
antioxidant defense mechanism, is seen in this 
disease. Toxic oxygen metabolites are scavenged 
by antioxidant enzymes such as super oxide 
dismutase (SOD) and glutathione peroxidase 
(GPX). SOD reacts directly with H2O2 and then 
enzymes (Catalase and GPX) come to practice. 
Thus, these three enzymes, in addition to specific 
roles, work together against oxidant factors[5,8,9]. 
Vitamin E is the most important fat soluble 
antioxidant and considered as the primary step for 
antioxidant defense system. Numerous studies 
have demonstrated reduced serum level of this 
vitamin in beta-thalassemic patients[10-12]. 
     One study conducted on beta-thalassemia 
intermedia patients indicated that vitamin E 
supplementation improved balance of the 
antioxidant system and inhibited the process of 
lipid peroxidation in patients[10]. In addition to 
vitamin E, zinc deficiencies in beta- thalassemia 
major patients have been reported in some 
studies[11,13-20]. Zinc plays several profoundly and 
biologically important roles such as causing 
structural effects in more than 300 
metalloenzymes like super oxide dismutase. It also 
plays different antioxidant roles in the body[21,22]. 
Specific dietary recommendations for thalassemic 
patients minimize consumption of iron in the diet, 
and unfortunately result in the reduction of zinc 
intake[23]. Furthermore, chelator factors 
administered to prevent the accumulation of iron, 
cause an excretion effect on zinc in these 
patients[7,24,25]. 
     Micronutrient deficiencies, especially of vitamin 
E and zinc in beta-thalassemia major patients have 
been reported frequently. However, there is no 
published data about supplementation of these 
nutrients in thalassemia major patients. 
     So, we conducted a trial to investigate the joint 
and separate effects of vitamin E and zinc 
supplementation on antioxidant status such as 
GPX, SOD and total antioxidant capacity [TAC] in 
beta thalassemia major patients. 
Subjects and Methods  
This double blind randomized clinical trial was 
carried out on 120 beta-thalassemic major 
patients older than 18 years admitted to Taleghani 
and Amiralmomenin hospitals in the Golestan 
province (northern Iran) in 2009. All patients 
were characterized for having beta globin gene 
mutation.   
     Inclusion criteria were the history of 
continuous treatment with blood transfusion and 
Desferal as a chelator agent. Exclusion criteria 
were diabetes mellitus, smoking, hepatitis B and C 
and consumption of any supplements at least 
three months before the study.  
     The patients were randomly assigned into four 
groups including 30 subjects in each group using a 
random allocation method (random allocation 
method was a random permuted block or block 
balanced randomization using 8 characters blocks 
containing A, B, C and D). The first and second 
groups were asked to take a supplement of 220 
mg zinc sulfate containing 50 mg zinc daily for 
three months and 400 mg vitamin E supplement 
daily for three months. The third group took both 
supplements in similar doses. The fourth (control) 
group received no supplement.  
     Information about the demographic 
characteristics was obtained by questionnaire.      
Weight and height of subjects were measured.      
The body mass index (BMI) was calculated as 
weight [kg]/height [m]. 
     Blood samples were obtained from subjects 
after a 12-hour fasting, just before they received 
transfusion at beginning and end of the study, and 
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stored at -70 C until assay. Vitamin E and zinc 
therapy in thalassemic patients started 
immediately after the first transfusion.  
     Serum vitamin E level was measured by HPLC 
(Knuer Germany)[7]. In order to determine serum 
zinc concentration, the samples were collected in 
trace metal-free tubes to avoid contamination. 
Serum zinc was analyzed by flame atomic 
absorption spectrophotometry (Chem’s tech 
analytical UK, 2000-A.A.S)[26].  
     In order to assess the enzyme activity of SOD 
and GPX, the whole blood was rinsed three times 
with 0.9% saline normal. Activities of GPX and 
SOD of RBC were assessed by RANCEL and 
RANSOL (RANDOX, UK) kits. TAC was assessed by 
TAC (RANDOX, UK) kits. 
     The ethical committee of Tabriz University of 
Medical Sciences approved the study protocol.     
Written informed consent was obtained from all 
patients. 
     Statistical analysis was carried out on Statistical 
Package for Social Sciences (SPSS for Windows, 
release 11.0, 2002, SPSS, Chicago, IL, USA). Data 
were presented as mean±SD. Paired t-test was 
used for comparison of the mean for changes of 
different variables before and after intervention 
phases. Significant level was set 0.05 and all the 
statistical tests were carried out as two sided. 
Findings 
One hundred and twenty subjects including 57 
males and 63 females participated in this study.  
     The mean (±SD) age for all groups was 21.1 
(±9.7) years. Males' mean±SD age was 21.6 ± 3.8 
and for females it was 22.2 ± 4.6 years. 
     Serum zinc concentration in group 1 and 3, was 
significantly increased (P<0.007 and P<0.005, 
respectively). Serum concentration of vitamin E, in 
group 2 and 3 was significantly increased 
(P<0.001). Mean GPX activity in groups 1, 2, and 3 
showed significant decrease (P<0.015, P<0.032 
and P<0.029, respectively).  
     Mean BMI in groups 1, 2, and 3 revealed 
significantly positive changes (P<0.001). 
     Mean SOD activity and serum TAC did not show 
significant changes in any of the studied groups. 
No significant difference was seen in fourth 
(control) group, which did not use any 
supplements (Table 1). 
Discussion 
Red blood cells in thalassemics have morphologic 
abnormalities, which result in increased 
susceptibility of thalassemic red cells to the 
exogenous peroxidant threat. Two mechanisms for 
inadequate peroxidant defense in thalassemics are 
insufficient vitamin E levels in red blood cells and 
plasma, and decreased activity of several enzymes 
including SOD and GPX, which are the first line of 
defense against oxidant stress[7]. 
     According to the results (Table1), mean serum 
levels of vitamin E in all groups at beginning of the 
study were lower than the normal range[27]. 
     Vitamin E deficiency in thalassaemias is 
attributed to its increased consumption pursuant 
to the oxidative stress[5,7]; Chronic hepatic iron 
overloads, while causing a substantial reduction of 
serum lipids, can also lead to concurrent reduction 
of serum vitamin E[28].     Some studies have 
reported a serum zinc deficiency in beta 
thalassemia patients, which was related to 
hyperzincuria resulted from the release of Zn from 
hemolyzed red cells[18,19,20]. 
     In our studied subjects, 16% had a serum zinc 
deficiency (data are not shown); however, mean 
serum zinc was not low. Similarly, Mehdizadeh et 
al also did not report a zinc deficiency in beta 
thalassemic patients[29]. 
     Absence of predominant zinc deficiency in our 
patients may have resulted from regular 
transfusion therapy. 
     Our findings indicate that supplementation with 
Zn, vitamin E or both of these causes a significant 
increase in serum level of zinc in the first group, 
increased serum vitamin E in the second group, 
and increased serum zinc and vitamin E levels in 
the third group with no significant difference in 
the control group. Therefore, these interventions, 
especially vitamin E supplementation had 
favorable effects on serum vitamin E levels in 
patients, considering that base level of vitamin E 
in serum of all studied groups was lower than the 
normal limit. 
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     Oxidative stress is the result of an imbalance 
between free radical production and reduced 
degradation[30]. An increased oxidant stress and a 
decreased antioxidant status promote 
peroxidative damage to cell and organelle 
membranes. It is well documented that 
disturbances of oxidant-antioxidant balance occur 
in hemoglobinopathies, especially in thalassemia 
and sickle cell diseases[31]. Removal of toxic 
oxygen metabolites is the putative function of 
antioxidant enzymes such as SOD and GPX. It has 
already been demonstrated that oxidative stress 
induces antioxidative enzymes, including SOD and 
GPX[5]. Our findings confirm this. As indicated in 
Table 1, prior to interventions, SOD and GPX 
activities in all groups were much higher than in 
those of healthy subjects[31,32]. Significant increase 
in catalytic activities of SOD and GPX also were 
found in beta-thalassemic erythrocytes of beta-
thalassemic carriers in the study of Filiz et al[31].  
     The increased activity of SOD in beta 
thalassemia may be involved in scavenging the 
superoxide radical (O2-), thereby producing more 
hydrogen peroxide in the erythrocytes.  
     The increased activity of GPX in beta-
thalassemia may be involved in detoxifying 
hydroxyl radical (OH-). This finding suggests that 
high iron produces an oxidative stress in cells, 
which respond by increasing their antioxidant 
defenses. The increase of intracellular antioxidant 
enzymes might be hypothesized to be a direct 
effect of increased intracellular iron on gene 
expression[5].  
     Based on our results (Table 1), SOD and GPX 
activities in subjects were also higher than normal 
limits at the end of the study. However, GPX 
activity showed a significant reduction in all 
treated groups. Therefore, all three types of 
interventions had protective effects on this 
enzyme, and were effective in elevating the 
antioxidant status. These findings confirm the 
results of other studies[31,32]. Pfeifer et al reported 
that after vitamin E administration, thalassemic 
patients presented a significant reduction in levels 
of erythrocyte RBC-reactive oxygen species (ROS) 
and serum thiobarbituric acid reactive substances 
(TBARS), and concluded that it could be useful for 
reducing oxidative damage in other target organs 
of beta-thalassemia intermediate patients[33]. Mei-
ling Cheng et al demonstrated that supplemen-
tation with vitamin E prevents oxidative damage 
to low-density-lipoprotein (LDL) and erythrocytes 
in beta thalassemia patients[34]. 
     In addition to vitamin E, it was established that 
zinc can reduce the iron-mediated oxidation of 
lipids (including red blood cells), proteins, and 
DNA[35]. The precise antioxidant role of zinc is 
unclear, but two mechanisms were proposed; first 
the competitive effect of zinc with iron and copper 
on the surface of cell membrane for special protein 
binding which is specific for preventing the 
production of the toxic OH radical. The second one 
is binding to the –SH groups in some proteins and 
preventing them from oxidation[36]. Sidhu et al 
found that in zinc and protein deficient rat the 
activities of GPX, catalase, and peroxidation of 
lipids were increased[37]. Our results confirmed 
antioxidant effect of zinc (Table 1), as seen in zinc 
supplemented group GPX activity also reduced 
significantly.  
     According to the results (Table 1) SOD activity 
in groups did not change significantly after 
supplementation. The study of Rahul Naithani, et 
al in beta-thalassemia major patients showed that 
SOD increases significantly, and it may be a 
compensatory mechanism to keep formation of 
superoxide anions checked to combat the 
oxidative stress[32]. Kessab-Chekir, et al observed 
that iron, ferritin, SOD, GPX and TBARS were 
increased in 56 beta-thalassemic patients; 
however, vitamin E and TRAP reduced 
considerably[5]. Meral, et al reported that because 
of increased lipid peroxidation in beta thalassemic 
patients a compensatory increase will be seen in 
SOD and GPX activity[38].  
     Our findings confirmed the results of above 
mentioned study, and showed higher SOD 
activities in patients. Similar to our findings, 
Carpino et al indicated despite the increased 
activity of SOD in transfusion dependent 
thalassemics, TAC did not change[39]. 
     Dissayabutra et al reported despite vitamin E 
and vitamin C supplementation in beta-
thalassemia major patients, TAC did not change 
during the study period[40]. It was suggested that 
various methods, including TAC, developed to 
measure the total antioxidant capacity of serum, 
have been indicated as useful tools to predict the 
risk of free radical-induced tissue damage. 
     Nevertheless,  with  thalassaemia  patients, such  
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an approach appears unsuitable. Changes in 
contributors such as uric acid and bilirubin, the 
levels of which increase in thalassaemia because 
of hemolysis, may mask marked changes in other 
essential antioxidants[28]. It seems that these 
conditions also contributed to unchanged SOD 
activity and TAC   in our subjects.  
     Low BMI in beta-thalassemic patients is 
common[41]. According to findings (Table 1) BMI of 
all treated subjects increased significantly, which 
was indicative of well-being of patients and 
positive effect of supplementation. Similar results 
were seen in Das et al study[12].  
     It should be noticed that, we did not evaluate 
other components of the cellular antioxidant 
defense system such as catalase, glutathione, uric 
acid, bilirubin, vitamin C, etc. If more enzymatic 
and non enzymatic antioxidants were measured, 
we could have a complete evaluation of the 
antioxidant status in these patients. So, they are 
considered as limitations of our study.  
Conclusion 
Our findings indicated that beta-thalassemic 
patients were under enhanced oxidative stress 
condition, and vitamin E deficiency. 
Administration of selective antioxidants revealed 
helpful effects, especially on serum vitamin E and 
GPX activity as components of antioxidant system, 
and on general well-being of the subjects. Further 
studies are suggested with different dose and 
duration of antioxidant supplements to determine 
their benefits in beta thalassemic patients. 
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